This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: niacin

News from the American College of Cardiology Scientific Session 2013

April 2013 Br J Cardiol 2013;20:54-5. Online First

News from the American College of Cardiology Scientific Session 2013

BJCardio Staff

Abstract

PREVAIL not presented but eases safety concerns on Watchman The PREVAIL trial of a new device which closes the left atrial appendage in the heart (Watchman®, Boston Scientific) attracted huge controversy at the ACC meeting when it was removed from the programme within an hour of its presentation because of an embargo break by the sponsor, Boston Scientific. But the slides and a press release were still made available to the media, and preliminary results appear to suggest some reassurance on safety concerns generated in a previous study. The device, which is implanted via a trans-septal catheter-based delivery system, is already available in

| Full text
News from the American Heart Association Scientific Sessions 2009

February 2010 Br J Cardiol 2010;17:13-18

News from the American Heart Association Scientific Sessions 2009

BJCardio editorial staff

Abstract

ARBITER 6: niacin superior to ezetimibe for slowing atherosclerosis Use of extended-release niacin resulted in a significant benefit on atherosclerosis compared with ezetimibe in patients already taking statins in the ARBITER 6-HALTS trial. The trial, presented at the meeting by Dr Allen Taylor (Medstar Research Institute, Washington DC, US), compared two distinct lipid-modifying strategies in patients with known vascular disease already on statins who had LDL-cholesterol levels <100 mg/dL (2.56 mmol/L) and moderately low HDL-cholesterol levels (<50 mg/dL [1.28 mmol/L]). Among the 363 patients enrolled in the study, half were randomised

| Full text

November 2009 Br J Cardiol 2009;16:269-71

Niacin shows plaque regression

BJCardio editorial staff

Abstract

The recently published study (J Am Coll Cardiol 2009;54:1787-94), was conducted by a group led by Dr Justin Lee (University of Oxford). In the study, 71 patients with low high-density lipoprotein (HDL) cholesterol and vascular disease were randomised to modified release nicotinic acid (uptitrated to 2 g daily), or placebo. All patients were already taking statins. Magnetic resonance imaging (MRI) was performed at baseline and at six and 12 months, with blood samples taken at the time of MRI. Results showed that the primary end point of absolute change in carotid artery wall area at one year was reduced by 1.64 mm2 in the niacin group compare

| Full text

July 2008 Br J Cardiol 2008;15:210-14

Clinical experience with prolonged-release nicotinic acid in statin-treated patients managed in Ireland

Michael O’Reilly, Ulrike Hostalek, John Kastelein

Abstract

Introduction Cardiovascular events remain the leading cause of morbidity and mortality in developed countries, and the treatment of dyslipidaemia is central to the overall management of cardiovascular risk.1,2Although correction of hypercholesterolaemia remains the principal target for correction of the lipid profile, dyslipidaemia is heterogeneous in presentation, with many patients presenting with low high-density lipoprotein-cholesterol (HDL-C) in addition to elevated concentrations of ApoB-containing lipoproteins. A survey carried out in 11 European countries identified low HDL-C (<1.03 mmol/L in men and <1.29 mmol/L in women) in ab

| Full text

March 2006 Br J Cardiol 2006;13:131-6

The failure of LDL cholesterol reduction and the importance of reverse cholesterol transport. The role of nicotinic acid

H Robert Superko

Abstract

No content available

| Full text
Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now